Literature DB >> 1972315

The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis.

D J Adler1, B I Korelitz.   

Abstract

We report our observations over 18 years (1970-1988) on 81 compliant patients with resistant ulcerative colitis who received 91 courses of treatment with 6-mercaptopurine (6-MP) for at least 4 months. These represent 172 patient years of 6-MP therapy and 308 years of observation after initiating 6-MP. In all patients, treatment with sulfasalazine and steroids had failed; most (96%) were dependent on systemic steroids and still symptomatic. The mean treatment period with 6-MP was 1.8 yr. In 42 out of 87 courses (48%) of 6-MP steroids could be eliminated, and in another 11 (13%) could be significantly reduced, for a total response rate of 61%. When four patients not on steroids were included, the response rate was 63%. The steroids were discontinued after a mean treatment time of 10 wk, and the 42 patients remained steroid free for the remainder of 6-MP treatment. Follow-up data after discontinuing 6-MP in 29 patients from this group show the mean time to relapse was 21 months with a median time of 12.5 months. We conclude that 6-MP is effective in inducing remission, eliminating steroids, and maintaining remission in many patients with refractory ulcerative colitis. Patients should be made aware of this option before colectomy is recommended.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972315

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

Review 1.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Authors:  Kara Bradford; David Q Shih
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?

Authors:  S Ghosh; R Chaudhary; M Carpani; R J Playford
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 3.  Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?

Authors:  B E Sands
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

4.  Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?

Authors:  Luc J J Derijks; Daniel W Hommes
Journal:  Curr Gastroenterol Rep       Date:  2006-04

5.  Enduring Value of Thiopurines for Inflammatory Bowel Disease Therapy.

Authors:  Burton I Korelitz
Journal:  Dig Dis Sci       Date:  2017-02       Impact factor: 3.199

Review 6.  A practical guide to the management of distal ulcerative colitis.

Authors:  S Ardizzone; G Bianchi Porro
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

7.  [Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].

Authors:  I Caesar; V Gross; M Roth; T Andus; W Hohenberger; J Schölmerich
Journal:  Med Klin (Munich)       Date:  1997-06-15

Review 8.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 9.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.

Authors:  Burton I Korelitz
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.